17 recruiting. 17 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Recruiting 17 |
| Phase 2 | 2 | Recruiting 2 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-10-27 |
| Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities atorvastatin of dose level 1, atorvastatin of dose level 2, atorvastatin of dose level 3 - Kawasaki Disease, Coronary Artery Abnormalities | Phase 3 | Recruiting | Children's Hospital of Fudan University | 9 | 2026-06-08 | 2026-06-16 |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Cyclophosphamide, Standard of Care (SOC), Prednisone - Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA) | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 36 | 2025-11-10 | 2026-01-30 |
| BDB-001 Phase III Trial in ANCA-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Rituximab - ANCA Associated Vasculitis (AAV) | Phase 3 | Recruiting | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 300 | 2025-11-10 | 2026-08-13 |
| Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome Corticosteroids + Rivaroxaban, Corticosteroids alone - Behcet Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 134 | 2025-06-24 | 2026-04-23 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Rituximab, Tocilizumab, Tofacitinib - Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 42 | 2025-06-06 | 2026-04-03 |
| A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases Benralizumab - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) | Phase 3 | Recruiting | AstraZeneca | 14 | 2025-04-17 | 2026-10-28 |
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
| A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease Hemay005, Placebo - Behçet's Disease | Phase 3 | Recruiting | Ganzhou Hemay Pharmaceutical Co., Ltd | 162 | 2023-11-13 | 2025-04-08 |
| A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial Pioglitazone (ACTOS®), Placebo of Pioglitazone - ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 126 | 2023-10-24 | 2026-07-01 |
| A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment ANAKINRA, Intravenous immunoglobulin - Kawasaki Disease | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 84 | 2023-10-20 | 2024-02-28 |
| A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis Apremilast - Behçet's Disease, Juvenile Psoriatic Arthritis | Phase 3 | Recruiting | Amgen | 48 | 2023-03-23 | 2025-12-01 |
| Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease Apremilast, Placebo - Behçet Disease | Phase 3 | Recruiting | Amgen | 60 | 2021-09-09 | 2026-07-24 |
| Abatacept for the Treatment of Giant Cell Arteritis Abatacept, Placebo - Giant Cell Arteritis | Phase 3 | Recruiting | University of Pennsylvania | 78 | 2021-03-29 | 2026-08-20 |
| Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering Corticosteroids for Systemic Use - Giant Cell Arteritis | Phase 3 | Recruiting | University Hospital, Caen | 150 | 2021-03-03 | 2026-06-26 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Behcet Syndrome (4) · Churg-Strauss Syndrome (3) · Granulomatosis with Polyangiitis (3) · Giant Cell Arteritis (2) · Mucocutaneous Lymph Node Syndrome (2) · Oral Ulcer (2) · Arteritis (1) · Arthritis, Juvenile (1) · Asthma (1) · Autoimmune Diseases (1) · Glomerulonephritis, IGA (1) · Hypereosinophilic Syndrome (1) · IgA Vasculitis (1)
Cardiovascular Diseases (17) · Skin Diseases (17) · Skin Diseases, Vascular (17) · Skin and Connective Tissue Diseases (17) · Vascular Diseases (17) · Autoimmune Diseases (11) · Immune System Diseases (11) · Systemic Vasculitis (8) · Hemic and Lymphatic Diseases (6) · Lymphatic Diseases (5) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Eye Diseases (4) · Genetic Diseases, Inborn (4)
Rituximab (3) · Adrenal Cortex Hormones (2) · Cyclophosphamide (2) · Prednisone (2) · apremilast (2) · benralizumab (2) · Abatacept (1) · Azathioprine (1) · BDB001 (1) · Cyclic Nucleotide Phosphodiesterases, Type 4 (1) · Hemay005 (1) · Immunoglobulins, Intravenous (1) · Interleukin 1 Receptor Antagonist Protein (1) · Pioglitazone (1) · Rivaroxaban (1)
Assistance Publique - Hôpitaux de Paris (4) · Amgen (2) · AstraZeneca (2) · Alexion Pharmaceuticals, Inc. (1) · Children's Hospital of Fudan University (1) · Ganzhou Hemay Pharmaceutical Co., Ltd (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Ottawa Hospital Research Institute (1) · Robert Spiera, MD (1) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (1) · University Hospital, Caen (1) · University of Pennsylvania (1)
France (8) · China (5) · United States (5) · Canada (4) · Israel (4) · Turkey (Türkiye) (4) · Italy (3) · Spain (3) · Greece (2) · India (2) · Netherlands (2) · Poland (2) · South Korea (2) · United Kingdom (2) · Argentina (1)
Alexandre Karras (1) · Benjamin Terrier, MD, PhD (1) · Carol A Langford, MD, MHS (1) · Chen Chu, MD (1) · David Massicotte-Azarniouch, MD, MSc (1) · Jeffrey P Krischer, PhD (1) · Lindsay Lally, MD (1) · Minghui Zhao, M.D. (1) · Peter A Merkel, MD, MPH (1) · Robert F Spiera, MD (1) · Zhanguo Li, Doctor (1)
2023 (3), 2018 (1)